-
Coping with DILI challenge in drug discovery and development
The liver is a vital organ responsible for several essential functions, […]
-
Meet the team: Part 5
We are happy to introduce our newest team member, Katja Pasternack, […]
-
Welcoming the new harmonized ICH M12 guideline for drug interaction studies
On May 21st 2024, the International Council for Harmonization (ICH) published […]
-
Admescope 2023 lookback
“Welcome to 2024! We couldn’t wait for 2023 to end,” was […]
-
Overcoming Hurdles in ADME Research for PROTACs
Targeted protein degraders (TPDs), also known as proteolysis targeting chimeras (PROTACs), […]
-
Meet the team: Part 4
Since the founding of the company over 12 years ago, Admescope […]
-
Exploring Oligonucleotide-Based Therapies: ADME CRO Perspective
In recent decades, the pharmaceutical industry has witnessed a remarkable surge […]
-
Are you close to candidate selection? An IND/IMPD enabling drug developability assessment may help in compound consideration.
Drug discovery and development is a complex and iterative process that […]
-
Greetings from the new CSO
A year and a half after stepping down from the CEO […]
-
Integrated drug discovery and development services – tailored to your needs
Throughout drug discovery and development, there are numerous scientific hoops to […]
-
Admescope 2022 lookback
2022 was full of action, and it marked the most successful […]
-
I have become an Admescopian!
Time goes by fast when having fun – such a cliché, […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
